Boston Scientific Q2 beats: $3.599B revenue (+11% reported), adj. EPS $0.53 vs guidance $0.48-$0.50

BOSTON SCIENTIFIC CORP

2023-Q2 EPS reported $0.39 revenue$6,988,000,000

Revenue $3.599B, +11% reported, +11.6% organic; beat guidance of 6.5-8.5% reported.
GAAP EPS $0.18 (GAAP net income $261M); adjusted EPS $0.53 vs guidance $0.48-$0.50.
Cardiovascular segment grew 12.2% reported; MedSurg grew 9.0% reported.
Full-year 2023 guidance raised: reported revenue growth ~10.5-11.5%, adj. EPS $1.96-$2.00.
Q3 guidance: reported revenue growth 8.5-10.5%, adj. EPS $0.46-$0.48.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BOSTON SCIENTIFIC CORP reported the second quarter ended June 30, 2023 results: revenue $3.599 billion, net income $261 million, EPS $0.18 per share (EPS).

Period: the second quarter ended June 30, 2023
Revenue: $3.599 billion
Net income: $261 million
EPS: $0.18 per share (EPS)
Result: reported results

Exact text from the filing

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational 1 basis and 11.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted 3 EPS of $0.53 for the period, compared to $0.44 a year ago.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-23-000041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.